Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
1,485
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Metastasis immune-based scores predict patient survival

Bernhard Mlecnika Laboratory of Integrative Cancer Immunology, INSERM, Paris, France;b Equipe Labellisée Ligue Contre le Cancer, Paris, France;c Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France;d Inovarion, Paris, FranceView further author information
,
Gabriela Bindeaa Laboratory of Integrative Cancer Immunology, INSERM, Paris, France;b Equipe Labellisée Ligue Contre le Cancer, Paris, France;c Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, FranceView further author information
,
Marc Van den Eyndee Department of Medical Oncology and Hepato-gastroenterology, Cliniques Universitaires Saint-Luc/Université Catholique de Louvain (Uclouvain), Brussels, BelgiumView further author information
&
Jérôme Galona Laboratory of Integrative Cancer Immunology, INSERM, Paris, France;b Equipe Labellisée Ligue Contre le Cancer, Paris, France;c Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, FranceCorrespondence[email protected]
View further author information
Article: 1806000 | Received 29 Jul 2020, Accepted 31 Jul 2020, Published online: 20 Aug 2020

References

  • Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE, Soubrane O, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–3. doi:10.1093/annonc/mdl386. PMID: 17060484.
  • Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G, Buttard B, Rothe F, Willard-Gallo K, Haller A, et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature. 2019;571:570–575. doi:10.1038/s41586-019-1330-0. PMID: 31243362.
  • Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L, Buttard B, Morgand E, Bruni D, Jouret-Mourin A, et al. Evolution of metastases in space and time under immune selection. Cell. 2018;175:751–765 e716. doi:10.1016/j.cell.2018.09.018. PMID: 30318143.
  • Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, Lafontaine L, Haicheur N, Marliot F, Debetancourt D, et al. Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival. J Natl Cancer Inst. 2018;110:97–108. doi:10.1093/jnci/djx123. PMID: 28922789.
  • Van den Eynde M, Mlecnik B, Bindea G, Fredriksen T, Church SE, Lafontaine L, Haicheur N, Marliot F, Angelova M, Vasaturo A, et al. The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients. Cancer Cell. 2018;34:1012–1026 e1013. doi:10.1016/j.ccell.2018.11.003. PMID: 30537506.
  • Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology. 2013;2:e26621. doi:10.4161/onci.26621. PMID: 24498550.
  • Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med. 2016;14:273. doi:10.1186/s12967-016-1029-z. PMID: 27650038.
  • Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pages F. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol. 2016;28:373–382. doi:10.1093/intimm/dxw021. PMID: 27121213.
  • Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol. 2008;84:981–987. doi:10.1189/jlb.1107773. PMID: 18559950.
  • Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011;33:335–340. doi:10.1007/s00281-011-0264-x. PMID: 21461991.
  • Pagès F, André T, Taieb J, Vernerey D, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L, et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol. 2020;31:921–929. doi:10.1016/j.annonc.2020.03.310. PMID: 32294529.
  • Marliot F, Chen X, Kirilovsky A, Sbarrato T, El Sissy C, Batista L, Van den Eynde M, Haicheur-Adjouri N, Anitei MG, Musina AM, et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. J Immunother Cancer. 2020;8:e000272. doi:10.1136/jitc-2019-000272. PMID: 32448799.
  • Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011;71:5670–5677. doi:10.1158/0008-5472.CAN-11-0268. PMID: 21846824.
  • Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Kroemer G. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2012;1:179–188. doi:10.4161/onci.1.2.19026. PMID: 22720239. 2011ONCOIMM0105 [pii].

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.